SA Asks: Which oncology companies are attractive M&A targets?
Source: SeekingAlpha
2025-05-30 15:00:49 ET
More on Gilead Sciences, Bristol-Myers Squibb Company , etc.
- Bristol-Myers Squibb: This Undervalued Dog Needs An Option Collar
- Bristol-Myers: Among The Cheapest Pharma Names, Now Yielding Above 5%
- Bristol-Myers Squibb At ASCO 2025: A Resilient Play Amid Market Turbulence
- Global cancer drug sales growth to slow amid patent cliffs: report
- Autolus Therapeutics gets EU endorsement for leukemia treatment
Read the full article on Seeking Alpha
For further details see:
SA Asks: Which oncology companies are attractive M&A targets?
Tema Oncology ETF
NASDAQ: CANC
CANC Trading
0.64% G/L:
$36.73 Last:
14,430 Volume:
$36.53 Open:
CANC Latest News
December 02, 2025 06:00:00 am
Tema's Oncology ETF (CANC) Surpasses $100m in Assets Amidst Strong 2025 Performance
